Mga Batayang Estadistika
| LEI | 549300ZLMVP4X0OGR454 |
| CIK | 1395064 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 31, 2025 |
Statement Statement on Inadvertent Abstract Disclosure for Oveporexton (TAK-861) by World Sleep Congress Osaka, JAPAN and CAMBRIDGE, Massachusetts, July 31, 2025 – An embargoed version of an abstract for our Phase 3 TAK-861-3002 study (RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1, which is slated to be presented at the upcoming World Sleep 2025 congress in September, was inadvertently published by the World Sleep Congress on their website. |
|
| July 30, 2025 |
(Million USD, except EPS) FY2025 Q1 USD Translation Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2025 Q1 Reported Results with CER % Change A-4 FY2025 Q1 Core Results with CER % Change A-5 FY2025 Q1 Reconciliation from Reported to Core A-6 FY2024 Q1 Reconciliation from Reported to Core A |
|
| July 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of July 2025 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 14, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 9, 2025 |
This document is an English translation of the original Japanese version, prepared solely for the convenience of reference. |
|
| July 9, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 8, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 2, 2025 |
TAKEDA U.S. FINANCING, INC. 5.200% Senior Notes due 2035 Exhibit 4.6 THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERENCED AND REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM IN ACCORDANCE WITH THE PROVISIONS OF THE INDENTURE AND THE TERMS OF THIS NOTE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE TO NOMINEES OF THE DEPOSI |
|
| July 2, 2025 |
Exhibit 4.5 TAKEDA U.S. FINANCING, INC. The Issuer TAKEDA PHARMACEUTICAL COMPANY LIMITED The Guarantor THE BANK OF NEW YORK MELLON Trustee THE BANK OF NEW YORK MELLON, LONDON BRANCH London Paying Agent THE BANK OF NEW YORK MELLON SA/NV, DUBLIN BRANCH Registrar INDENTURE Dated as of July 2, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1. |
|
| July 2, 2025 |
Exhibit 5.3 July 2, 2025 Takeda U.S. Financing, Inc., 500 Kendall Street, Cambridge, Massachusetts 02142, United States of America. Takeda Pharmaceutical Company Limited, 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan. Ladies and Gentlemen: We are acting as United States counsel to Takeda U.S. Financing, Inc., a Delaware corporation (the “Company”) and Takeda Pharmaceutical Company |
|
| July 2, 2025 |
Takeda Pharmaceutical Company Limited Registration Statement on Form F-3 Exhibit 5.4 July 2, 2025 Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan Takeda Pharmaceutical Company Limited Registration Statement on Form F-3 Dear Sirs: We have acted as legal counsel to Takeda Pharmaceutical Company Limited (the “Guarantor”) with respect to the laws of Japan in connection with the issue by Takeda U.S. Financing, Inc. (the “Co |
|
| July 2, 2025 |
TAKEDA U.S. FINANCING, INC. 5.900% Senior Notes due 2055 Exhibit 4.7 THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERENCED AND REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM IN ACCORDANCE WITH THE PROVISIONS OF THE INDENTURE AND THE TERMS OF THIS NOTE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE TO NOMINEES OF THE DEPOSI |
|
| July 2, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38757 Takeda Pharmaceutical Company Limited (Translation of registrant’s name into English) 1-1, Nihonbashi Honcho 2-chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 1, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 30, 2025 |
2025 Annual Integrated Report Contents 3 About this report 4 Takeda at a glance 5 Message from our President and Chief Executive Officer 6 Message from our Chief Financial Officer 7 Corporate Philosophy 9 Our approach to business 12 Corporate philosophy metrics 14 Commitment to the patient 17 Commitment to people 20 Commitment to the planet 24 How We Create Value 25 Groundbreaking scientific disco |
|
| June 27, 2025 |
US$1,650,000,000 5.200% GUARANTEED NOTES DUE 2035 FINAL TERM SHEET Dated June 26, 2025 Filed Pursuant to Rule 433 Registration Statement Nos. 333-288301 and 333-288301-01 TAKEDA U.S. FINANCING, INC. US$1,650,000,000 5.200% GUARANTEED NOTES DUE 2035 FINAL TERM SHEET Dated June 26, 2025 Issuer: Takeda U.S. Financing, Inc. (the “Issuer”) Guarantor: Takeda Pharmaceutical Company Limited (the “Guarantor”) Security: US$1,650,000,000 5.200% Guaranteed Notes due 2035 (the “Notes”) Expected |
|
| June 27, 2025 |
Filed Pursuant to Rule 424(b)(2) Registration No. 333-288301 and 333-288301-01 PROSPECTUS SUPPLEMENT to Prospectus dated June 25, 2025. TAKEDA U.S. FINANCING, INC. $1,650,000,000 5.200% Guaranteed Notes due 2035 $750,000,000 5.900% Guaranteed Notes due 2055 Fully and Unconditionally Guaranteed by TAKEDA PHARMACEUTICAL COMPANY LIMITED Takeda U.S. Financing, Inc., a Delaware corporation (“TUSFI” or |
|
| June 27, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables F-3 TAKEDA PHARMACEUTICAL CO LTD Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt $1,650,000,000 5. |
|
| June 26, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-288301 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where such offer or sale |
|
| June 25, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 25, 2025 |
List of Subsidiary Issuers of Guaranteed Securities Exhibit 22 Exhibit 22 List of Subsidiary Issuers of Guaranteed Securities The following subsidiary of Takeda Pharmaceutical Company Limited (the “Guarantor”) will be the issuer of senior securities to be fully and unconditionally guaranteed by the Guarantor which may be sold pursuant to the registration statement of which this exhibit is part: Takeda U.S. Financing, Inc. |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No. |
|
| June 25, 2025 |
Exhibit 25.1 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = == = = = UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BAN |
|
| June 25, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables F-3 TAKEDA PHARMACEUTICAL CO LTD Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Senior Debt Securities of Takeda Pharmaceutical Company Limited 457(r) 0. |
|
| June 25, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No.333-239422, No.333-260543, No.333-265887 and No.333-272970) on Form S-8 of our reports dated June 25, 2025, with respect to the consolidated financial statements of Takeda Pharmaceutical Company Limited and the effectiveness of internal control over |
|
| June 25, 2025 |
EXHIBIT 13.1 Certification Pursuant to 18 U.S.C. §1350, the undersigned officer of Takeda Pharmaceutical Company Limited (the “Company”) hereby certifies, to such officer’s knowledge, that the Company’s annual report on Form 20-F for the year ended March 31, 2025 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and |
|
| June 25, 2025 |
Exhibit 1.2 TAKEDA U.S. FINANCING, INC., AS ISSUER TAKEDA PHARMACEUTICAL COMPANY LIMITED, AS GUARANTOR [$][€][ ] [ ]% Notes due [ ] FORM OF UNDERWRITING AGREEMENT [ ], 20[ ] [Name(s) of Representatives] Underwriting Agreement [ ], 20[ ] [insert name(s) of Representative(s)] As Representatives of the several Underwriters c/o [ ] Ladies and Gentlemen: Introductory. Takeda U.S. Financing, Inc., a cor |
|
| June 25, 2025 |
Exhibit 25.2 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NE |
|
| June 25, 2025 |
EXHIBIT 12.2 CERTIFICATION I, Milano Furuta, certify that: 1.I have reviewed this annual report on Form 20-F of Takeda Pharmaceutical Company Limited; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 25, 2025 |
Exhibit 4.2 TAKEDA U.S. FINANCING, INC. The Issuer TAKEDA PHARMACEUTICAL COMPANY LIMITED The Guarantor THE BANK OF NEW YORK MELLON Trustee THE BANK OF NEW YORK MELLON, LONDON BRANCH London Paying Agent THE BANK OF NEW YORK MELLON SA/NV, DUBLIN BRANCH Registrar INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 1.1. Definitio |
|
| June 25, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No.333-280469) on Form F-3 of our reports dated June 25, 2025, with respect to the consolidated financial statements of Takeda Pharmaceutical Company Limited and the effectiveness of internal control over financial reporting. /s/KPMG AZSA LLC Tokyo, Japa |
|
| June 25, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 25, 2025 |
EXHIBIT 12.1 CERTIFICATION I, Christophe Weber, certify that: 1.I have reviewed this annual report on Form 20-F of Takeda Pharmaceutical Company Limited; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead |
|
| June 25, 2025 |
EXHIBIT 13.2 Certification Pursuant to 18 U.S.C. §1350, the undersigned officer of Takeda Pharmaceutical Company Limited (the “Company”) hereby certifies, to such officer’s knowledge, that the Company’s annual report on Form 20-F for the year ended March 31, 2025 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and |
|
| June 12, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 10, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 6, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 2, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 2, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| May 28, 2025 |
a2025convocation Notice of Convocation of the 149th Annual General Meeting of Shareholders Date June 25, 2025 (Wednesday), 10:00 a. |
|
| May 28, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 28, 2025 |
Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. |
|
| May 28, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 28, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 28, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 28, 2025 |
1 CEO Shareholder Letter 2025 Dear fellow Takeda shareholders, This will be my last annual letter as president and CEO of Takeda. |
|
| May 28, 2025 |
1 Better Health, Brighter Future TAKEDA’S EXECUTIVE COMPENSATION OVERVIEW Takeda’s executive compensation strategy supports our position as a patient-focused, values-based, R&D-driven global biopharmaceutical company. |
|
| May 14, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Takeda Yakuhin Kogyo Kabushiki Kaisha (Exact name of the registrant as specified in its charter) Takeda Pharmaceutical Company Limited (Translation of Registrant’s name into English) Japan 001-38757 Not Applicable (State of other jurisdiction of incorporation or organization) (Commission F |
|
| May 8, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 8, 2025 |
stock-compensationplan 1 Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025 Osaka, JAPAN, May 8, 2025 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Company”) announced that the meeting of the Board of Directors held today resolved to continue the stock compensation plan which was introduced as a long-term incentive plan for members of the Board of Directors (the “Directors”) in 2016, as well as to continue the stock grant system which was introduced in 2014 as a global long-term incentive plan for Company Management in Japan (collectively with the stock compensation plan for Directors, the “Plans”). |
|
| May 8, 2025 |
(Million USD, except EPS) USD Translation Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2024 Reported Results with CER % Change A-4 FY2024 Q4 (Jan-Mar) Reported Results with CER % Change A-5 FY2024 Core Results with CER % Change A-6 FY2024 Q4 (Jan-Mar) Core Results with CER % Ch |
|
| May 8, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of May 2025 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| April 22, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| April 14, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| April 1, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| March 26, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| March 13, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| March 3, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| March 3, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| February 13, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| January 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of January 2025 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| January 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| January 30, 2025 |
(Million USD, except EPS) FY2024 Q3 YTD USD Translation Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2024 Q3 YTD Reported Results with CER % Change A-4 FY2024 Q3 (Oct-Dec) Reported Results with CER % Change A-5 FY2024 Q3 YTD Core Results with CER % Change A-6 FY2024 Q3 (Oct-Dec) Core Results |
|
| January 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| January 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| January 30, 2025 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| December 18, 2024 |
Amendment Extraordinary Report Exhibit 99.1 Amendment Extraordinary Report [Cover] [Document Filed] Extraordinary Report (Inline XBRL attached to the Amendment Extraordinary Report dated December 18, 2024) [Filed with] Director, Kanto Local Finance Bureau [Filing Date] September 26, 2024 [Company Name] Takeda Pharmaceutical Company Limited [Title and Name of Representative] Christophe Weber, Representative Director, President & |
|
| December 18, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| December 13, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| December 13, 2024 |
Takeda R&D Day 2024 Focus on Late-stage Pipeline & Market Opportunity Friday, December 13th, 2024 Tokyo This material is prepared and distributed solely for the purpose of providing information about Takeda's management or business to shareholders, investors, and analysts, and is not intended to induce purchase or prescription of any specific drugs and other products. |
|
| December 2, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| December 2, 2024 |
Page 1 of 6 Business Report: The 148th Interim Period Dear Takeda Shareholders, I am thankful for your support and continued confidence in Takeda. |
|
| October 31, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 31, 2024 |
Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of October 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 |
|
| October 31, 2024 |
(Million USD, except EPS) FY2024 H1 USD Translation Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2024 H1 Reported Results with CER % Change A-4 FY2024 Q2 (Jul-Sep) Reported Results with CER % Change A-5 FY2024 H1 Core Results with CER % Change A-6 FY2024 Q2 (Jul-Sep) Core Results with CE |
|
| October 31, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of October 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| September 26, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address |
|
| July 31, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of July 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 31, 2024 |
(Million USD, except EPS) FY2024 Q1 USD Translation Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations A-1 Reconciliations and Other Financial Information FY2024 Q1 Reported Results with CER % Change A-4 FY2024 Q1 Core Results with CER % Change A-5 FY2024 Q1 Reconciliation from Reported to Core A-6 FY2023 Q1 Reconciliation from Reported to Core A |
|
| July 31, 2024 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s (“Takeda”) beneficial ownership of the issuer’s common stock (“Common Stock”) consists of 1,475,121 shares of Common Stock held by Takeda Ventures, Inc. (“TVI”). TVI is wholly owned directly by Takeda Pharmaceuticals U.S.A., Inc., which |
|
| July 31, 2024 |
XLO / Xilio Therapeutics, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 – Exit Filing)* XILIO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98422T100 (CUSIP Number) July 31, 20241 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| July 31, 2024 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Xilio Therapeutics, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party |
|
| July 10, 2024 |
This document is an English translation of the original Japanese version, prepared solely for the convenience of reference. |
|
| July 10, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 5, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-38757 Takeda Pharmaceutical Company Limited (Translation of registrant’s name into English) 1-1, Nihonbashi Honcho 2-chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 5, 2024 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 5.650% Senior Notes due 2044 EXHIBIT 4.2 THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERENCED AND REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM IN ACCORDANCE WITH THE PROVISIONS OF THE INDENTURE AND THE TERMS OF THIS NOTE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE TO NOMINEES OF THE DEPOSI |
|
| July 5, 2024 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 5.650% Senior Notes due 2054 EXHIBIT 4.3 THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERENCED AND REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM IN ACCORDANCE WITH THE PROVISIONS OF THE INDENTURE AND THE TERMS OF THIS NOTE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE TO NOMINEES OF THE DEPOSI |
|
| July 5, 2024 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 5.800% Senior Notes due 2064 EXHIBIT 4.4 THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERENCED AND REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM IN ACCORDANCE WITH THE PROVISIONS OF THE INDENTURE AND THE TERMS OF THIS NOTE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE TO NOMINEES OF THE DEPOSI |
|
| July 5, 2024 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED 5.300% Senior Notes due 2034 EXHIBIT 4.1 THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERENCED AND REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN DEFINITIVE FORM IN ACCORDANCE WITH THE PROVISIONS OF THE INDENTURE AND THE TERMS OF THIS NOTE, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE TO NOMINEES OF THE DEPOSI |
|
| July 2, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 1, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 1, 2024 |
2024 Annual Integrated Report Fiscal Year Ended March 31, 2024 Takeda is a global values-based, research and development (R&D)-driven biopharmaceutical company committed to achieving our corporate purpose: better health for people and a brighter future for the world. |
|
| June 28, 2024 |
Issuer Free Writing Prospectus Filed by Takeda Pharmaceutical Company Limited Pursuant to Rule 433 Registration Statement No. |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM 424B2 TAKEDA YAKUHIN KOGYO KABUSHIKI KAISHA (Exact Name of Registrant as Specified in Its Charter) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Debt $1,100,000,000 5. |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM 424B2 TAKEDA YAKUHIN KOGYO KABUSHIKI KAISHA (Exact Name of Registrant as Specified in Its Charter) TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Debt $1,100,000,000 5. |
|
| June 27, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-280469 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where such offer or sale |
|
| June 26, 2024 |
EXHIBIT 13.2 Certification Pursuant to 18 U.S.C. §1350, the undersigned officer of Takeda Pharmaceutical Company Limited (the “Company”) hereby certifies, to such officer’s knowledge, that the Company’s annual report on Form 20-F for the year ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024 As filed with the Securities and Exchange Commission on June 26, 2024 Registration No. |
|
| June 26, 2024 |
Exhibit 25.1 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NE |
|
| June 26, 2024 |
COMPENSATION RECOUPMENT POLICY Exhibit 97.1 COMPENSATION RECOUPMENT POLICY TAKEDA PHARMACEUTICAL COMPANY LIMITED I.Policy for Recovery upon Restatement of Financial Statements A.In the event the Company is required to prepare a Restatement, the following shall apply: (i)Company will recover reasonably promptly any Erroneously Awarded Compensation from its Covered Executives (which, for purposes of this Section, are its Executiv |
|
| June 26, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 26, 2024 |
EXHIBIT 13.1 Certification Pursuant to 18 U.S.C. §1350, the undersigned officer of Takeda Pharmaceutical Company Limited (the “Company”) hereby certifies, to such officer’s knowledge, that the Company’s annual report on Form 20-F for the year ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and |
|
| June 26, 2024 |
Exhibit 1.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED [$][€][ ] [ ]% Notes due [ ] FORM OF UNDERWRITING AGREEMENT [ ], 20[ ] [Name(s) of Representatives] Underwriting Agreement [ ], 20[ ] [insert name(s) of Representative(s)] As Representatives of the several Underwriters c/o [ ] Ladies and Gentlemen: Introductory. Takeda Pharmaceutical Company Limited, a joint stock corporation organized under the la |
|
| June 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table FORM F-3 TAKEDA YAKUHIN KOGYO KABUSHIKI KAISHA (Exact Name of Registrant as Specified in Its Charter) TAKEDA YAKUHIN KOGYO KABUSHIKI KAISHA (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximu |
|
| June 26, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No.333-239422, No.333-260543, No.333-265887 and No.333-272970) on Form S-8 of our reports dated June 26, 2024, with respect to the consolidated financial statements of Takeda Pharmaceutical Company Limited and the effectiveness of internal control over |
|
| June 26, 2024 |
Global Insider Trading Policy Version 1.1 Page: 1 of 7 TET sponsor: Yoshihiro Nakagawa Effective Date: June 7, 2024 Printed or downloaded documents must be verified against the effective version. Table of Contents 1. Purpose ............................................................................... 1 2. Scope….................................................................................... |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 26, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 26, 2024 |
EXHIBIT 12.1 CERTIFICATION I, Christophe Weber, certify that: 1.I have reviewed this annual report on Form 20-F of Takeda Pharmaceutical Company Limited; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead |
|
| June 26, 2024 |
EXHIBIT 12.2 CERTIFICATION I, Milano Furuta, certify that: 1.I have reviewed this annual report on Form 20-F of Takeda Pharmaceutical Company Limited; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 17, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 11, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 10, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 7, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 7, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 3, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 3, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| May 29, 2024 |
Page 1 of 13 CEO Shareholder Letter 2024 Dear Takeda Shareholder, On behalf of the Takeda Board of Directors, I am delighted to invite you to our Annual Shareholders Meeting on June 26, 2024. |
|
| May 29, 2024 |
- 1 - Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. |
|
| May 29, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 29, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 29, 2024 |
Notice of Convocation of the 148th Ordinary General Meeting of Shareholders Date: June 26, 2024 (Wednesday), 10:00 a. |
|
| May 29, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 29, 2024 |
1 Better Health, Brighter Future TAKEDA’S EXECUTIVE COMPENSATION OVERVIEW Takeda’s executive compensation structure reflects our position as a patient-focused, values-based, R&D- driven global biopharmaceutical company. |
|
| May 29, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 21, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of May 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 9, 2024 |
1 Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2024 Osaka, JAPAN, May 9, 2024 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Company”) announced that the meeting of the Board of Directors held today resolved to continue the stock compensation plan which was introduced as a long-term incentive plan for members of the Board of Directors (the “Directors”) in 2016, as well as to continue the stock grant system which was introduced in 2014 as a global long-term incentive plan for Company Management in Japan (collectively with the stock compensation plan for Directors, the “Plans”). |
|
| May 9, 2024 |
(Million USD, except EPS) USD Translation Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2023 Reported Results with CER % Change A-3 FY2023 Q4 (Jan-Mar) Reported Results with CER % Change |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Takeda Yakuhin Kogyo Kabushiki Kaisha (Exact name of the registrant as specified in its charter) Takeda Pharmaceutical Company Limited (Translation of Registrant’s name into English) Japan 001-38757 (State of other jurisdiction of incorporation or organization) (Commission File Number) 1-1 |
|
| April 19, 2024 |
1 News Release U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease − ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease OSAKA, Japan April 19, 2024 and CAMBRID |
|
| April 19, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| April 15, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| April 10, 2024 |
PHAT / Phathom Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment SC 13D/A 1 sc13da041024.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome C |
|
| April 1, 2024 |
PHAT / Phathom Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment SC 13D/A 1 sc13da040124.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome C |
|
| March 27, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| February 9, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| February 5, 2024 |
SC 13G/A 1 tak131246sc13ga3.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Takeda Pharmaceutical Company Limited (Name of Issuer) Common Stock (Title of Class of Securities) 874060205 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check |
|
| February 2, 2024 |
Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-866 |
|
| February 1, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| February 1, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| February 1, 2024 |
FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U. |
|
| January 25, 2024 |
PHAT / Phathom Pharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment SC 13D/A 1 sc13da012524.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Phathom Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 71722W107 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome C |
|
| January 25, 2024 |
EX-1 2 exhibit1012524.htm EX-1 Exhibit 1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of January 24, 2024 (the “Effective Date”), by and among Medicxi IV LP, a Jersey limited partnership (“Medicxi IV”), Medicxi Co-Invest IV LP, a Jersey limited partnership (“Medicxi Co-Invest”) (Medicxi IV and Medicxi Co-Invest each being a “Purchaser” and together being the |
|
| January 19, 2024 |
EX-99.1 2 exhibit991011924.htm EX-99.1 Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s (“Takeda”) beneficial ownership of the issuer’s common stock (“Common Stock”) consists of 1,842,977 shares of Common Stock held by Takeda Ventures, Inc. (“TVI”). TVI is wholly owned directly by Take |
|
| January 19, 2024 |
EX-99.2 3 exhibit992011924.htm EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Equillium, Inc. and further agree to the filing of this agreement as an Exhibit th |
|
| January 19, 2024 |
EQ / Equillium, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13G Passive Investment SC 13G 1 sc13g011924.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EQUILLIUM, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 29446K106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| January 16, 2024 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| December 14, 2023 |
cgreport Corporate Governance Report December 14, 2023 Takeda Pharmaceutical Company Limited https://www. |
|
| December 14, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| November 30, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| November 30, 2023 |
April 1, 2023 - September 30, 2023 Takeda Pharmaceutical Company Limited TSE : 4502 NYSE : TAK The 147th (interim period) 1 Dear Shareholders, I am grateful for your continued support as we enter the second half of fi scal year 2023. |
|
| November 13, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| October 30, 2023 |
Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of October 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 |
|
| October 30, 2023 |
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2023 H1 Reported Results with CER % Change A-3 FY2023 Q2 (Jul-Sep) Reported Results with CER % Chan |
|
| October 26, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of October 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 26, 2023 |
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate Change, Free Cash Flow, and U.S. Dollar Convenience Translations A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2023 H1 Reported Results with CER % Change A-3 FY2023 Q2 (Jul-Sep) Reported Results with CER % Chan |
|
| October 26, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 18, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 18, 2023 |
alofiseltoplineresults Press Release Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas OSAKA, Japan, October 18, 2023, and CAMBRIDGE, Massachusetts, October 17, 2023 — Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. |
|
| October 18, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 18, 2023 |
irishtaxsettlement 1 Better Health, Brighter Future Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire OSAKA, Japan, October 18, 2023– Takeda (TSE:4502/NYSE:TAK) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. |
|
| October 2, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| September 28, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address |
|
| September 11, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address |
|
| August 1, 2023 |
Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of August 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 |
|
| July 27, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of July 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 27, 2023 |
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2023 Q1 Reported Results with CER % Change A-3 FY2023 Q1 Core Results with CER % Change A-4 FY2023 Q1 Reconciliation from Reported to Cor |
|
| July 12, 2023 |
cgreport Corporate Governance Report July 12, 2023 Takeda Pharmaceutical Company Limited https://www. |
|
| July 12, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 6, 2023 |
integratedreport Fiscal Year ended March 31, 2023 2023 ANNUAL INTEGRATED REPORT 2 TA K E DA I S A G L O B A L values-based, research and development (R&D)-driven biopharmaceutical company committed to achieving our corporate purpose: better health for people and a brighter future for the world. |
|
| July 6, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| July 3, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 28, 2023 |
Exhibit 1.2 Board of Directors Charter Article 1: (Purpose) The Board of Directors of Takeda Pharmaceutical Company Limited (the “Company”) shall comply with this charter unless otherwise prescribed by the applicable laws and ordinances, or the Articles of Incorporation. Article 2: (Meetings) Meetings of the Board of Directors shall be convened by the Chairman of the Board of Directors. (2) In the |
|
| June 28, 2023 |
EXHIBIT 12.1 CERTIFICATION I, Christophe Weber, certify that: 1.I have reviewed this annual report on Form 20-F of Takeda Pharmaceutical Company Limited; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 Registration No. |
|
| June 28, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 28, 2023 |
EXHIBIT 12.2 CERTIFICATION I, Costa Saroukos, certify that: 1.I have reviewed this annual report on Form 20-F of Takeda Pharmaceutical Company Limited; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadin |
|
| June 28, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statements (No. 333-239422, No. 333-260543 and No.333-265887) on Form S-8 of our reports dated June 28, 2023, with respect to the consolidated financial statements of Takeda Pharmaceutical Company Limited and the effectiveness of internal control over financial rep |
|
| June 28, 2023 |
EXHIBIT 13.1 Certification Pursuant to 18 U.S.C. §1350, the undersigned officer of Takeda Pharmaceutical Company Limited (the “Company”) hereby certifies, to such officer’s knowledge, that the Company’s annual report on Form 20-F for the year ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and |
|
| June 28, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 28, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 28, 2023 |
EXHIBIT 13.2 Certification Pursuant to 18 U.S.C. §1350, the undersigned officer of Takeda Pharmaceutical Company Limited (the “Company”) hereby certifies, to such officer’s knowledge, that the Company’s annual report on Form 20-F for the year ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and |
|
| June 28, 2023 |
Exhibit 99.2 RULES OF THE TAKEDA PHARMACEUTICAL COMPANY LIMITED EMPLOYEE STOCK PURCHASE PLAN As Amended as of April 1, 2023 RULES OF THE TAKEDA PHARMACEUTICAL COMPANY LIMITED EMPLOYEE STOCK PURCHASE PLAN Table of Contents Contents Page 1. Introduction 1 2. Definitions 1 3. Eligibility 3 4. Enrollment 3 5. Grant of Purchase Rights 5 6. Exercise of Purchase Rights and Purchase of American Depositary |
|
| June 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Takeda Pharmaceutical Company Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(5) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock Rule 457(c) and Rule 457(h) 10,000,000(3) $32. |
|
| June 28, 2023 |
exhibit44062823 Exhibit 4.4 CONFIDENTIAL Execution Version [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. STOCK PURCHASE AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICALS U.S.A., INC. AND NIMBUS THERAPEUTICS, LLC DATED AS OF DECEMBER 13, 2022 T |
|
| June 23, 2023 |
convocation Notice of Convocation of the 147th Ordinary General Meeting of Shareholders Date: June 28, 2023 (Wednesday), 10:00 a. |
|
| June 23, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 23, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 9, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| June 1, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pr |
|
| May 30, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 30, 2023 |
convocation Notice of Convocation of the 147th Ordinary General Meeting of Shareholders Date: June 28, 2023 (Wednesday), 10:00 a. |
|
| May 30, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 30, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 30, 2023 |
internetdisclosure Please note that the following is an English translation of the original Japanese version, prepared only for the convenience of shareholders residing outside Japan. |
|
| May 30, 2023 |
shareholderletter Letter to Shareholders 1 May 2023 01 Crediting the Power of Our People Unleashing Data, Digital and Technology in Our Transformation Efforts A Steadfast Focus on the Future of Our Planet Living Our Values: Corporate Governance Update Our Commitment to Delivering on Our Purpose: Better Health for People, Brighter Future for the World Appendix 02 12 03 13 14 15 16 17 05 07 09 10 In |
|
| May 30, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 26, 2023 |
CALA / Calithera Biosciences Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Calithera Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 13089P101 (CUSIP Number) Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo MO 103-8668 Yoshihiro Nak |
|
| May 17, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Takeda Yakuhin Kogyo Kabushiki Kaisha (Exact name of the registrant as specified in its charter) Takeda Pharmaceutical Company Limited (Translation of Registrant’s name into English) Japan 001-38757 Not Applicable (State of other jurisdiction of incorporation or organization) (Commission F |
|
| May 11, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 11, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of May 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of pri |
|
| May 11, 2023 |
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2022 Reported Results with Actual and CER % Change A-3 FY2022 Q4 (Jan-Mar) Reported Results with Actual and CER % Change A-4 FY2022 Core |
|
| March 30, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| March 20, 2023 |
6-K 1 form6k032023.htm FORM 6-K FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, To |
|
| March 16, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| March 16, 2023 |
a2023qdengainvestorcall QDENGA: TRANSFORMING DENGUE PREVENTION President, Global Portfolio Division March 15, 2023 EST / March 16, 2023 JST Ramona Sequeira Vice President, Head of Dengue Global Program Derek Wallace Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School Eng Eong Ooi Guest Speaker: This material is prepared and distributed solely for the purpose of providing information about Takeda's management or business to shareholders, investors, and analysts, and is not intended to induce purchase or prescription of any specific drugs and other products. |
|
| March 1, 2023 |
ARTICLES OF INCORPORATION OF TAKEDA PHARMACEUTICAL COMPANY LIMITED Chapter I General Provisions Exhibit 99.1 [The following is the translation of the Articles of Incorporation of Takeda Pharmaceutical Company Limited, the latest amendment to which was made on 1st March 2023.] ARTICLES OF INCORPORATION OF TAKEDA PHARMACEUTICAL COMPANY LIMITED Chapter I General Provisions Article 1. (Corporate Name) The Company shall be named Takeda Yakuhin Kogyo Kabushiki Kaisha, displayed in English as Taked |
|
| March 1, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of p |
|
| February 10, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| February 9, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| February 7, 2023 |
Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-866 |
|
| February 3, 2023 |
OVID / Ovid Therapeutics Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* OVID THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 690469101 (CUSIP Number) July 1, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Takeda Pharmaceutical Company Limited (Name of Issuer) Common Stock (Title of Class of Securities) 874060205 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 3, 2023 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Day One Biopharmaceuticals, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, ea |
|
| February 3, 2023 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Ovid Therapeutics Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party t |
|
| February 3, 2023 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s beneficial ownership of the reported securities is comprised of zero shares of Common Stock held by Takeda Ventures, Inc., a wholly owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned direct |
|
| February 3, 2023 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s beneficial ownership of the reported securities is comprised of zero shares of Common Stock held by Takeda Ventures, Inc., a wholly owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned direct |
|
| February 3, 2023 |
Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. Takeda Pharmaceutical Company Limited’s beneficial ownership of the reported securities is comprised of 1,781,996 shares of the Issuer’s Common Stock that it holds directly, 5,750,000 shares of the Issuer’s Common Stock held by Takeda Pharmaceuticals U.S.A., Inc. (“TPUSA”) and |
|
| February 3, 2023 |
DAWN / Day One Biopharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 Exit Filing)* DAY ONE BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 23954D109 (CUSIP Number) June 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 3, 2023 |
DAWN / Day One Biopharmaceuticals, Inc. / TAKEDA PHARMACEUTICAL CO LTD Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 Exit Filing)* DAY ONE BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 23954D109 (CUSIP Number) June 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 3, 2023 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Day One Biopharmaceuticals, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, ea |
|
| February 2, 2023 |
Exhibit 99.1 FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2022 Q3 YTD Reported Results with Actual and CER % Change A-3 FY2022 Q3 (Oct-Dec) Reported Results with Actual and CER % Change A-4 FY202 |
|
| February 2, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2023 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| January 10, 2023 |
Committed to Long-term Growth & Shareholder Returns 41st Annual J.P. Morgan Healthcare Conference President & CEO January 9th, 2023 Christophe Weber For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session a nd any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“ Takeda”) regarding this |
|
| January 10, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| January 5, 2023 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| December 21, 2022 |
This document is a translation of a press release issued by Shonan iPark, Takeda, IIF and Mitsubishi Corp. |
|
| December 21, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant?s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| December 13, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant?s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| December 13, 2022 |
Exhibit 99.1 (Attachment) News Release Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics ?With Phase 3 Study in Psoriasis Expected to Start in 2023, NDI-034858 Has the Potential to Demonstrate Best-in-class Efficacy and Safety in Psoriasis As Well As Multiple Other Immune-Mediated Diseases, Including Inflammatory Bowel Disease |
|
| December 8, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant?s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| November 30, 2022 |
April 1, 2022 - September 30, 2022 Takeda Pharmaceutical Company Limited TSE : 4502 NYSE : TAK The 146th (interim period) Dear Shareholders, As we reach the end of the first half of FY2022 (April 1, 2022 to September 30, 2022), I want to thank you for your continued support. |
|
| November 30, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address o |
|
| November 4, 2022 |
Table of Contents FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of November 2022 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-866 |
|
| October 27, 2022 |
Exhibit 99.1 ? FINANCIAL APPENDIX Definition of Non-IFRS Measures Definition of Core Financial Measures, Constant Exchange Rate change, and Free Cash Flow A-1 Definition of EBITDA/Adjusted EBITDA and Net Debt A-2 Reconciliations and Other Financial Information FY2022 H1 Reported Results with Actual and CER % Change A-3 FY2022 Q2 (Jul-Sep) Reported Results with Actual and CER % Change A-4 FY2022 H1 |
|
| October 27, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of October 2022 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant?s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 14, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant’s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| October 4, 2022 |
FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant?s name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of |
|
| August 23, 2022 |
Better Health, Brighter Future Takeda?s QDENGA?? (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure OSAKA, Japan, August 23, 2022 ? Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced the company?s dengue vaccine, QDENGA? (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age. |
